In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R

Molecular Immunology

Volumn 46, Issue 7, 2009, Pages 1481-1487

  Sirven, Philemon ^a   Castelli, Florence Anne ^a   Probst, Alicia ^a   Szely, Natacha ^a   Maillere, Bernard ^a  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

CD4+ T helper lymphocytes; Epitopes; HLA class II; Poxvirus

Indexed keywords

EPITOPE; HLA DR ANTIGEN; PROTEIN A33R; PROTEIN B5R; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; POXVIRUS INFECTION; PRIORITY JOURNAL; VACCINIA VIRUS;

ANTIGENS, VIRAL; BLOOD DONORS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES, T-LYMPHOCYTE; HELA CELLS; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; PEPTIDE FRAGMENTS; PROTEIN BINDING; SUBSTRATE SPECIFICITY; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS;

ANIMALIA; POXVIRIDAE;

EID: 62549117315     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.12.016     Document Type: Article

References (40)

1. Assarsson E., Sidney J., Oseroff C., Pasquetto V., Bui H.H., Frahm N., Brander C., Peters B., Grey H., and Sette A. A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J. Immunol. 178 (2007) 7890-7901
2. Bell E., Shamim M., Whitbeck J.C., Sfyroera G., Lambris J.D., and Isaacs S.N. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325 (2004) 425-431
3. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., Snyder J.T., Ahlers J.D., Franchini G., Moss B., and Berzofsky J.A. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 100 (2003) 9458-9463
4. Calvo-Calle J.M., Strug I., Nastke M.D., Baker S.P., and Stern L.J. Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection. PLoS Pathog. 3 (2007) 1511-1529
5. Castelli F.A., Leleu M., Pouvelle-Moratille S., Farci S., Zarour H.M., Andrieu M., Auriault C., Menez A., Georges B., and Maillere B. Differential capacity of T cell priming in naive donors of promiscuous CD4(+) T cell epitopes of HCV NS3 and Core proteins. Eur. J. Immunol. 37 (2007) 1513-1523
6. Cohen W.M., Pouvelle-Moratille S., Wang X.F., Farci S., Munier G., Charron D., Menez A., Busson M., and Maillere B. Scanning the HIV genome for CD4+ T cell epitopes restricted to HLA-DP4, the most prevalent HLA class II molecule. J. Immunol. 176 (2006) 5401-5408
7. Combadiere B., Boissonnas A., Carcelain G., Lefranc E., Samri A., Bricaire F., Debre P., and Autran B. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J. Exp. Med. 199 (2004) 1585-1593
8. Davies D.H., Liang X., Hernandez J.E., Randall A., Hirst S., Mu Y., Romero K.M., Nguyen T.T., Kalantari-Dehaghi M., Crotty S., Baldi P., Villarreal L.P., and Felgner P.L. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl. Acad. Sci. USA 102 (2005) 547-552
9. Davies D.H., Wyatt L.S., Newman F.K., Earl P.L., Chun S., Hernandez J.E., Molina D.M., Hirst S., Moss B., Frey S.E., and Felgner P.L. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J. Virol. 82 (2008) 652-663
10. Earl P.L., Cooper N., Wyatt L.S., Moss B., and Carroll M.W. Preparation of cell cultures and vaccinia virus stocks. Curr. Protoc. Mol. Biol. (2001) Chapter 16, Unit16
11. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., Nalca A., Hooper J.W., Whitehouse C.A., Schmitz J.E., Reimann K.A., and Franchini G. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11 (2005) 740-747
12. Engelmayer J., Larsson M., Subklewe M., Chahroudi A., Cox W.I., Steinman R.M., and Bhardwaj N. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 163 (1999) 6762-6768
13. Fang M., Cheng H., Dai Z., Bu Z., and Sigal L.J. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology 345 (2006) 231-243
14. Ferrier-Rembert A., Drillien R., Tournier J.N., Garin D., and Crance J.M. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine 26 (2008) 1794-1804
15. Fogg C., Lustig S., Whitbeck J.C., Eisenberg R.J., Cohen G.H., and Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78 (2004) 10230-10237
16. Galmiche M.C., Goenaga J., Wittek R., and Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254 (1999) 71-80
17. Golden J.W., and Hooper J.W. Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. Virology 377 (2008) 19-29
18. Henderson D.A., Inglesby T.V., Bartlett J.G., Ascher M.S., Eitzen E., Jahrling P.B., Hauer J., Layton M., McDade J., Osterholm M.T., O'Toole T., Parker G., Perl T., Russell P.K., and Tonat K. Smallpox as a biological weapon: medical and public health management Working Group on Civilian Biodefense. JAMA 281 (1999) 2127-2137
19. Heraud J.M., Edghill-Smith Y., Ayala V., Kalisz I., Parrino J., Kalyanaraman V.S., Manischewitz J., King L.R., Hryniewicz A., Trindade C.J., Hassett M., Tsai W.P., Venzon D., Nalca A., Vaccari M., Silvera P., Bray M., Graham B.S., Golding H., Hooper J.W., and Franchini G. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177 (2006) 2552-2564
20. Hooper J.W., Custer D.M., and Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306 (2003) 181-195
21. Hooper J.W., Thompson E., Wilhelmsen C., Zimmerman M., Ichou M.A., Steffen S.E., Schmaljohn C.S., Schmaljohn A.L., and Jahrling P.B. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78 (2004) 4433-4443
22. Jenkins D.E., Yasukawa L.L., Bergen R., Benike C., Engleman E.G., and Arvin A.M. Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination. J. Immunol. 162 (1999) 560-567
23. Jing L., Chong T.M., Byrd B., McClurkan C.L., Huang J., Story B.T., Dunkley K.M., Aldaz-Carroll L., Eisenberg R.J., Cohen G.H., Kwok W.W., Sette A., and Koelle D.M. Dominance and diversity in the primary human CD4 T cell response to replication-competent vaccinia virus. J. Immunol. 178 (2007) 6374-6386
24. Jing L., Chong T.M., McClurkan C.L., Huang J., Story B.T., and Koelle D.M. Diversity in the acute CD8 T cell response to vaccinia virus in humans. J. Immunol. 175 (2005) 7550-7559
25. Matsui M., Moriya O., Yoshimoto T., and Akatsuka T. T-bet is required for protection against vaccinia virus infection. J. Virol. 79 (2005) 12798-12806
26. Mitra-Kaushik S., Cruz J., Stern L.J., Ennis F.A., and Terajima M. Human cytotoxic CD4+ T cells recognize HLA-DR1-restricted epitopes on vaccinia virus proteins A24R and D1R conserved among poxviruses. J. Immunol. 179 (2007) 1303-1312
27. Oseroff C., Kos F., Bui H.H., Peters B., Pasquetto V., Glenn J., Palmore T., Sidney J., Tscharke D.C., Bennink J.R., Southwood S., Grey H.M., Yewdell J.W., and Sette A. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc. Natl. Acad. Sci. USA 102 (2005) 13980-13985
28. Oseroff C., Peters B., Pasquetto V., Moutaftsi M., Sidney J., Panchanathan V., Tscharke D.C., Maillere B., Grey H., and Sette A. Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve. J. Immunol. 180 (2008) 7193-7202
29. Pulford D.J., Gates A., Bridge S.H., Robinson J.H., and Ulaeto D. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine 22 (2004) 3358-3366
30. Putz M.M., Midgley C.M., Law M., and Smith G.L. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat. Med. 12 (2006) 1310-1315
31. Schuler-Thurner B., Schultz E.S., Berger T.G., Weinlich G., Ebner S., Woerl P., Bender A., Feuerstein B., Fritsch P.O., Romani N., and Schuler G. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195 (2002) 1279-1288
32. Snyder J.T., Belyakov I.M., Dzutsev A., Lemonnier F., and Berzofsky J.A. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J. Virol. 78 (2004) 7052-7060
33. Tang J., Murtadha M., Schnell M., Eisenlohr L.C., Hooper J., and Flomenberg P. Human T-cell responses to vaccinia virus envelope proteins. J. Virol. 80 (2006) 10010-10020
34. Terajima M., Cruz J., Raines G., Kilpatrick E.D., Kennedy J.S., Rothman A.L., and Ennis F.A. Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J. Exp. Med. 197 (2003) 927-932
35. Texier C., Pouvelle- Moratille S., Busson M., Charron D., Menez A., and Maillere B. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3 -DRB4 and -DRB5 molecules. Eur. J. Immunol. 31 (2001) 1837-1846
36. Texier C., Pouvelle S., Busson M., Herve M., Charron D., Menez A., and Maillere B. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol. 164 (2000) 3177-3184
37. Valmori D., Souleimanian N.E., Hesdorffer C.S., Old L.J., and Ayyoub M. Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4(+) T cells in cancer-free individuals. Clin. Immunol. 117 (2005) 161-167
38. Vollmar J., Arndtz N., Eckl K.M., Thomsen T., Petzold B., Mateo L., Schlereth B., Handley A., King L., Hulsemann V., Tzatzaris M., Merkl K., Wulff N., and Chaplin P. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24 (2006) 2065-2070
39. Xu R., Johnson A.J., Liggitt D., and Bevan M.J. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol. 172 (2004) 6265-6271
40. Zarour H.M., Maillere B., Brusic V., Coval K., Williams E., Pouvelle-Moratille S., Castelli F., Land S., Bennouna J., Logan T., and Kirkwood J.M. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 62 (2002) 213-218